Monsanto Corp's G.D. Searle and Co unitsaid it will report an operating loss for 1987, mainly due toexpenses for research and development.    Searle chairman Sheldon Gilgore said Searle's operatingloss in 1987 will be less than the 87 mln dlr operating loss in1986.    He said Searle's first quarter sales will be up 21.8 pct to179 mln dlrs from 147 mln dlrs in the year ago quarter. In 1986Searle's sales were 665 mln dlrs.    Gilgore said the company intends to have sales of threebillion dlrs by the mid-1990s.    He said the company anticipates approval in Japan, theU.S., Italy, Spain and the U.K. for its ulcer treatment drugCytotech.    He also said that in a paper not yet published the drug wasshown to prevent a flare-up of ulcers for a longer period oftime than Tagamet, made by SmithKline Beckman Corp &lt;SKB>.    Other drugs in Searle's pipeline include tissue plasminogenactivator (TPA), made by a different process than Genentech's&lt;GENE> TPA, expected to be approved for marketing this year.    Reuter&#3;